<SEC-DOCUMENT>0001062993-24-004754.txt : 20240228
<SEC-HEADER>0001062993-24-004754.hdr.sgml : 20240228
<ACCEPTANCE-DATETIME>20240228161424
ACCESSION NUMBER:		0001062993-24-004754
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240226
FILED AS OF DATE:		20240228
DATE AS OF CHANGE:		20240228

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Dreyer Scott
		CENTRAL INDEX KEY:			0001746251
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37372
		FILM NUMBER:		24695519

	MAIL ADDRESS:	
		STREET 1:		780 DEDHAM STREET, SUITE 800
		CITY:			CANTON
		STATE:			MA
		ZIP:			02021

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COLLEGIUM PHARMACEUTICAL, INC
		CENTRAL INDEX KEY:			0001267565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072
		BUSINESS PHONE:		781-713-3699

	MAIL ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COLLEGIUM PHARMACEUTICAL INC
		DATE OF NAME CHANGE:	20031020
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-02-26</periodOfReport>

    <issuer>
        <issuerCik>0001267565</issuerCik>
        <issuerName>COLLEGIUM PHARMACEUTICAL, INC</issuerName>
        <issuerTradingSymbol>COLL</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001746251</rptOwnerCik>
            <rptOwnerName>Dreyer Scott</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O COLLEGIUM PHARMACEUTICAL, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>100 TECHNOLOGY CENTER DRIVE</rptOwnerStreet2>
            <rptOwnerCity>STOUGHTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02072</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>EVP &amp; Chief Commercial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-02-26</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>9336</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>36.3754</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>139582</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-02-26</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>664</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>37.1530</value>
                    <footnoteId id="F3"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>138918</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023.</footnote>
        <footnote id="F2">The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.96 to $36.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.</footnote>
        <footnote id="F3">The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.01 to $37.50, inclusive.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Shirley R. Kuhlmann as Attorney-In-Fact For Scott Dreyer</signatureName>
        <signatureDate>2024-02-28</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
